V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330002705 | 330006781 | 1.86 | 102 | Not known (9) | 2017-01-06 | 2017-01-24 | BENDAMUSTINE + RITUXIMAB | N | N | 330011043 | BENDAMUSTINE + RITUXIMAB |
| 330002706 | 330006781 | 1.69 | 91 | Curative (C) | 2017-07-13 | 2017-07-14 | BENDAMUSTINE + RITUXIMAB | N | N | 330011043 | BENDAMUSTINE + RITUXIMAB |
| 330002707 | 330012628 | 1.67 | null | Adjuvant (A) | 2016-04-25 | 2016-04-25 | DOXORUBICIN | 2 | N | 330011064 | DOXORUBICIN |
| 330002708 | 330012628 | 1.56 | 85.9 | Neo-adjuvant (N) | 2013-11-26 | 2013-11-26 | CARBOPLATIN + PACLITAXEL | N | N | 330011064 | CARBOPLATIN + PACLITAXEL |
| 330002709 | 330001475 | 1.63 | 87.2 | Palliative (P) | null | 2014-10-14 | DOXORUBICIN | N | N | 330011074 | DOXORUBICIN |
| 330002710 | 330001476 | null | 46.8 | Palliative (P) | 2017-05-29 | 2017-05-31 | Liposomal Doxorubicin (Caelyx) | N | N | 330011083 | LIPOSOMAL DOXORUBICIN |
| 330002711 | 330006782 | 1.71 | 85.8 | null | 2016-02-20 | 2016-02-20 | Carboplatin + Paclitaxel (3 weekly) | N | N | 330011084 | CARBOPLATIN + PACLITAXEL |
| 330002712 | 330006782 | 1.68 | 68.2 | Disease modification (D) | 2017-02-07 | 2017-02-07 | Liposomal Doxorubicin (Caelyx) | 2 | null | 330011084 | LIPOSOMAL DOXORUBICIN |
| 330002713 | 330006782 | 1.7 | 99.4 | Neo-adjuvant (N) | 2013-06-30 | 2013-07-01 | Cisplatin + Doxorubicin | N | N | 330011084 | CISPLATIN + DOXORUBICIN |
| 330002714 | 330006782 | 1.59 | 56.8 | Neo-adjuvant (N) | 2014-03-15 | 2014-03-15 | Cisplatin + Doxorubicin | N | N | 330011084 | CISPLATIN + DOXORUBICIN |
| 330002715 | 330006782 | 1.73 | 80.6 | Palliative (P) | 2017-08-22 | 2017-08-22 | Liposomal Doxorubicin (20mg/m2) | N | N | 330011084 | LIPOSOMAL DOXORUBICIN |
| 330002716 | 330006782 | 1.7 | 81 | null | 2016-02-15 | 2016-02-16 | Rituximab | N | N | 330011084 | RITUXIMAB |
| 330002717 | 330001477 | 1.69 | 57 | Neo-adjuvant (N) | 2015-12-26 | 2016-01-08 | Cisplatin + Doxorubicin | N | N | 330011128 | CISPLATIN + DOXORUBICIN |
| 330002725 | 330001479 | null | 60 | Disease modification (D) | 2013-10-11 | 2013-10-22 | Rituximab | N | N | 330011187 | RITUXIMAB |
| 330002726 | 330006784 | 1.7 | null | Palliative (P) | 2016-02-16 | 2016-02-21 | CARBOPLATIN + PACLITAXEL | 02 | N | 330011189 | CARBOPLATIN + PACLITAXEL |
| 330002727 | 330006784 | 1.8 | 108 | Palliative (P) | 2017-01-31 | 2017-01-31 | CARBOPLATIN | 02 | N | 330011189 | CARBOPLATIN |
| 330002728 | 330006784 | 1.7 | 71.4 | Curative (C) | 2018-02-17 | 2018-02-17 | Carboplatin AUC 6 - 10 | 02 | null | 330011189 | CARBOPLATIN |
| 330002729 | 330001480 | 1.67 | 71.9 | Neo-adjuvant (N) | 2017-09-13 | 2017-09-17 | Cisplatin + Doxorubicin | 2 | null | 330011197 | CISPLATIN + DOXORUBICIN |
| 330002730 | 330006785 | 1.7 | 89 | Palliative (P) | 2018-04-28 | 2018-05-03 | Liposomal Doxorubicin (Caelyx) | N | N | 330011198 | LIPOSOMAL DOXORUBICIN |
| 330002731 | 330006785 | 0 | 78.6 | Palliative (P) | 2014-10-06 | 2014-10-07 | Liposomal Doxorubicin (Caelyx) | 2 | N | 330011198 | LIPOSOMAL DOXORUBICIN |
| 330002732 | 330006785 | 1.71 | 60 | Palliative (P) | null | 2013-05-10 | Liposomal Doxorubicin (Caelyx) | null | null | 330011198 | LIPOSOMAL DOXORUBICIN |
| 330002733 | 330001481 | 1.58 | null | Curative (C) | 2013-11-12 | 2013-11-15 | Liposomal Doxorubicin (Caelyx) | N | null | 330011205 | LIPOSOMAL DOXORUBICIN |
| 330002734 | 330001481 | 1.86 | 94.8 | null | 2016-12-13 | 2016-12-20 | BENDAMUSTINE + RITUXIMAB | 2 | N | 330011205 | BENDAMUSTINE + RITUXIMAB |
| 330002735 | 330001482 | 1.7 | 60.5 | null | 2014-01-17 | 2014-01-17 | Carboplatin AUC 6 - 10 | N | N | 330011209 | CARBOPLATIN |
| 330002736 | 330001483 | 1.6 | 66 | Palliative (P) | 2015-09-10 | 2015-10-04 | Cisplatin + Doxorubicin | 02 | Y | 330011211 | CISPLATIN + DOXORUBICIN |
| 330002737 | 330001483 | null | 56 | Adjuvant (A) | 2016-05-24 | 2016-05-26 | Cisplatin + Doxorubicin | N | N | 330011211 | CISPLATIN + DOXORUBICIN |
| 330002738 | 330001483 | 1.72 | 72 | Curative (C) | 2017-10-22 | 2017-10-23 | Carboplatin AUC 6 - 10 | N | N | 330011211 | CARBOPLATIN |
| 330002739 | 330001483 | null | 64 | Neo-adjuvant (N) | 2017-10-13 | 2017-10-28 | CARBOPLATIN | N | N | 330011211 | CARBOPLATIN |
| 330002740 | 330001483 | 1.69 | null | Curative (C) | 2013-07-14 | 2013-07-14 | Carboplatin + Etoposide IV 3 day | 02 | N | 330011211 | CARBOPLATIN + ETOPOSIDE |
| 330002741 | 330001483 | 1.69 | 69 | Disease modification (D) | 2018-04-17 | 2018-06-08 | Rituximab | 2 | N | 330011211 | RITUXIMAB |
| 330002742 | 330001484 | 1.69 | 69.3 | null | 2016-04-24 | 2016-04-26 | Liposomal Doxorubicin (Caelyx) | 02 | N | 330011255 | LIPOSOMAL DOXORUBICIN |
| 330002743 | 330001484 | 1.68 | 69.5 | Disease modification (D) | 2016-08-31 | 2016-09-11 | BENDAMUSTINE + RITUXIMAB | N | N | 330011255 | BENDAMUSTINE + RITUXIMAB |
| 330002744 | 330001484 | 1.69 | 77.4 | Disease modification (D) | 2015-02-16 | 2015-02-25 | BENDAMUSTINE + RITUXIMAB | 2 | N | 330011255 | BENDAMUSTINE + RITUXIMAB |
| 330002745 | 330001484 | 1.61 | 61.1 | Adjuvant (A) | 2016-11-21 | 2016-11-22 | CARBOPLATIN + PACLITAXEL | N | N | 330011255 | CARBOPLATIN + PACLITAXEL |
| 330002746 | 330001484 | 1.57 | 57.4 | Adjuvant (A) | 2015-05-15 | 2015-05-16 | Doxorubicin 75mg/m2 | N | N | 330011255 | DOXORUBICIN |
| 330002747 | 330001484 | 1.79 | 69 | null | 2014-12-16 | 2014-12-22 | Cisplatin + Doxorubicin | 2 | N | 330011255 | CISPLATIN + DOXORUBICIN |
| 330002748 | 330001484 | 1.66 | 81.6 | Palliative (P) | 2014-09-21 | 2014-09-26 | Liposomal Doxorubicin 50mg/m2 | null | null | 330011255 | LIPOSOMAL DOXORUBICIN |
| 330002749 | 330001484 | 0 | 79 | Disease modification (D) | 2014-10-25 | 2014-11-01 | BENDAMUSTINE + RITUXIMAB | null | N | 330011255 | BENDAMUSTINE + RITUXIMAB |
| 330002750 | 330001485 | 1.6 | 77.9 | Palliative (P) | 2013-07-30 | 2013-08-06 | BENDAMUSTINE + RITUXIMAB | N | N | 330011285 | BENDAMUSTINE + RITUXIMAB |
| 330002751 | 330001486 | 1.72 | 75.1 | Curative (C) | 2014-03-16 | 2014-03-22 | Carboplatin + Etoposide iv&po | Y | N | 330011288 | CARBOPLATIN + ETOPOSIDE |
| 330002752 | 330001486 | 1.68 | 63.4 | Disease modification (D) | 2015-03-10 | 2015-03-31 | BENDAMUSTINE + RITUXIMAB | 02 | Y | 330011288 | BENDAMUSTINE + RITUXIMAB |
| 330002754 | 330001488 | 1.79 | 0 | Palliative (P) | 2016-11-19 | 2016-12-03 | Cisplatin + Doxorubicin | N | N | 330011299 | CISPLATIN + DOXORUBICIN |
| 330002755 | 330001488 | 1.73 | 75 | Adjuvant (A) | 2017-11-18 | 2017-10-11 | Cisplatin + Doxorubicin | 01 | N | 330011299 | CISPLATIN + DOXORUBICIN |
| 330002756 | 330001489 | 1.64 | 60.3 | Curative (C) | 2015-09-19 | 2015-09-20 | BENDAMUSTINE + RITUXIMAB | 2 | null | 330011312 | BENDAMUSTINE + RITUXIMAB |
| 330002757 | 330001489 | 1.66 | 78 | Palliative (P) | 2014-08-18 | 2014-08-25 | BENDAMUSTINE + RITUXIMAB | 02 | N | 330011312 | BENDAMUSTINE + RITUXIMAB |
| 330002762 | 330012131 | 1.6 | 81.55 | Not known (9) | null | 2015-04-07 | BENDAMUSTINE + RITUXIMAB | N | N | 330011346 | BENDAMUSTINE + RITUXIMAB |
| 330002763 | 330001491 | 1.63 | 69.9 | null | 2013-11-24 | 2013-11-25 | Doxorubicin 75mg/m2 | 2 | N | 330011354 | DOXORUBICIN |
| 330002764 | 330001491 | 1.78 | 64.6 | Curative (C) | 2016-05-20 | 2016-06-02 | CARBOPLATIN + ETOPOSIDE | N | N | 330011354 | CARBOPLATIN + ETOPOSIDE |
| 330002765 | 330001492 | 1.66 | 65.8 | Palliative (P) | 2017-10-22 | 2017-10-23 | Carboplatin + Paclitaxel (weekly) | N | N | 330011371 | CARBOPLATIN + PACLITAXEL |
| 330002766 | 330001492 | 1.67 | 85.8 | Neo-adjuvant (N) | 2016-10-23 | 2016-11-22 | Carboplatin + Etoposide iv&po | N | N | 330011371 | CARBOPLATIN + ETOPOSIDE |